Literature DB >> 3533973

Natural killer-cell activity, interferon-alpha 2 production, and interleukin-2 production in cyclosporine-treated and conventionally immunosuppressed human allograft recipients.

P J Guillou, G R Giles, C W Ramsden.   

Abstract

Natural killer (NK) activity, interferon (IFN)-alpha production, and interleukin-2 (IL-2) production were measured in renal transplant recipients undergoing immunosuppression with either azathioprine and steroids (Az + P) or cyclosporine (CyA). Overall, both IFN-alpha production and IL-2 production were impaired in these two groups compared with identical studies in healthy individuals. However, on the basis of control data these two patient groups were divided into those with "normal" NK activity and those with "low" NK activity. In the CyA group those with a low NK reaction produced less IL-2 and IFN-alpha than those with normal NK activity. No such relationship between cytokine production and NK activity was discerned in the Az + P group. These data conflict with in vitro studies, which have failed to demonstrate any effect of CyA on IFN-alpha production. In addition, they suggest that whereas cyclosporine influences NK activity in vivo by inhibiting cytokine production, other factors may play a role in impairing NK activity in conventionally immunosuppressed patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533973     DOI: 10.1007/bf00915376

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

1.  A monoclonal antibody for large-scale purification of human leukocyte interferon.

Authors:  D S Secher; D C Burke
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

2.  Glucocorticoid hormones inhibit DNA synthesis and enhance interferon production in human lymphoid cell line.

Authors:  G R Adolf; P Swetly
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Natural cell-mediated cytotoxicity and suppressor activity for natural cell-mediated cytotoxicity in long-term renal transplant patients.

Authors:  Y Ono; R H Kerman; B D Kahan
Journal:  Transplantation       Date:  1982-08       Impact factor: 4.939

5.  Are "natural killer" cells involved in allograft rejection?

Authors:  A Nemlander; E Saksela; P Häyry
Journal:  Eur J Immunol       Date:  1983-04       Impact factor: 5.532

6.  Phenotype of human alpha-interferon producing leucocytes identified by monoclonal antibodies.

Authors:  J Abb; H Abb; F Deinhardt
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

7.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Purified human interleukin-2 enhances induction of immune interferon.

Authors:  K T Pearlstein; M A Palladino; K Welte; J Vilcek
Journal:  Cell Immunol       Date:  1983-08       Impact factor: 4.868

9.  The effect of cyclosporin A on peripheral blood T cell subpopulations in renal allografts.

Authors:  P Sweny; N Tidman
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  5 in total

Review 1.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 3.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

4.  Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.

Authors:  J R Monson; C W Ramsden; G R Giles; T G Brennan; P J Guillou
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

5.  Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.

Authors:  Y Komada; S L Zhang; Y W Zhou; M Hanada; T Shibata; E Azuma; M Sakurai
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.